Page 13 - Noble-Virtual-Healthcare-2024

Atara Biotherapeutics, Inc.

SELECTED FINANCIAL ITEMS ATRA

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue 1.23 0.96 3.20 3.20 8.57
Gross Profit (61.15) (58.08) (50.13) (50.13) (219.48)
Gross Margin -4987% -6069% -1569% -1569% -2560%
EBIT (74.97) (71.41) (61.42) (61.42) (269.23)
EBIT Margin -6115% -7462% -1922% -1922% -3140%
Net Income to Common Shareholders (74.77) (71.11) (65.12) (65.12) (276.13)
Net Margin -6099% -7430% -2038% -2038% -3221%

Balance Sheet Key Items
Total Assets 302.08 246.44 165.50 165.50 165.50
Cash & Short Term Investments 48.74 45.90 25.84 25.84 25.84
% of Assets 16% 19% 16% 16% 16%
Current Assets -Total 224.18 172.32 101.87 101.87 101.87
% of Assets 74% 70% 62% 62% 62%
Total Liabilities 237.12 238.99 264.74 264.74 264.74
% of Assets 78% 97% 160% 160% 160%
Current Liabilities - Total 67.88 74.55 142.23 142.23 142.23
% of Assets 22% 30% 86% 86% 86%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 64.96 7.45 (99.23) (99.23) (99.23)
% of Assets 22% 3% -60% -60% -60%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (38.43) (52.80) (50.88) (50.88) (192.98)
Net Cash Flow - Investing (6.01) 49.48 40.20 40.20 123.87
Net Cash Flow - Financing 0.24 0.47 0.65 0.65 2.01

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference